Veterinary Practice’s Innovation Feature for February 2024 Covers FCGS Study

Veterinary Practice covered our pivotal study of allogeneic stem cell therapy targeting feline chronic gingivostomatitis (FCGS) as its February 2024 Innovation Feature. The article is co-authored by Gallant CEO Dr. Linda Black and Valentine Williams.

From Veterinary Practice
Breakthroughs in Stem Cell Therapy for Refractory Feline Chronic Gingivostomatitis and Beyond

This in-depth feature outlines the science behind uterine-derived mesenchymal stem cells (UMSCs) and their potential to address the immune-mediated nature of FCGS. It highlights early clinical signals from Gallant’s investigational therapy and examines how regenerative medicine may chart a new, disease-modifying path forward—not only for FCGS, but for other chronic inflammatory conditions in pets.